- Case report
- Open Access
Temporal lobe necrosis: a dwindling entity in a patient with nasopharyngeal cancer after radiation therapy
- Meera Dassarath†1, 2,
- Zhongyuan Yin†1,
- Jing Chen1,
- Hongli Liu1,
- Kunyu Yang1Email author and
- Gang Wu1
© Dassarath et al; licensee BioMed Central Ltd. 2011
Received: 22 November 2010
Accepted: 10 February 2011
Published: 10 February 2011
Our objective was to report a case of misdiagnosed temporal lobe necrosis (TLN) in a patient with nasopharyngeal cancer (NPC) after radiation therapy.
We report a case of a 45 years old Chinese woman who developed moderate to severe headache and dizziness 1 year after 2D radiation therapy for NPC. Subsequent MRI scanning revealed a big enhancing mass in the right temporal lobe. The initial diagnosis was metastatic or intracranial extension of NPC, or a primary intracranial malignancy. She was referred to the neurosurgery department where a maximal surgical resection of the lesion was performed. A diagnosis of TLN was made according to the final histology.
TLN still matters in the IMRT era. The diagnostic quagmire of TLN lies in its close resemblance to neoplasm on clinical presentation and imaging. Reviewing the patient's treatment plan to scrutinize the dose to the temporal lobes is an important prerequisite for diagnosis.
Worldwide, nasopharyngeal cancer (NPC) is most common in South China in the provinces of Guangdong, Guangxi, Fujian, Hunan, and Hong Kong. Its incidence in these regions is 30 per 100,000 compared to just 1 per 100,000 in Europe . Radiation therapy remains the main modality of treatment in NPC patients because of anatomic constraints and a high degree of radiosensitivity of this tumor [2–4]. However, temporal lobe necrosis (TLN) is one of the late side effects of radiation therapy that may be encountered in these patients.
The first case of radiation necrosis was described by Fischer and Holfelder in 1930 in a 45 year old patient treated with radiotherapy for basal cell epithelioma of the temporal region with a total dose of 6840 cGy . Lee et al. reported an incidence of up to 3% of TLN in patients after radiation therapy . This entity was once commonly encountered in the era when 2-D technique was widely used for the treatment of NPC. A significant decline of this complication has been observed since the introduction of Intensity-modulated Radiation Therapy (IMRT). Consequently, more and more physicians are oblivious of this complication due to its present rarity. However, knowledge about the possibility of its occurrence, as a delayed side effect of radiation therapy, is vital as it is associated with high morbidity and mortality. It has been seen to account for 65% of radiation related deaths from NPC in Hong Kong [7, 8] and the 5 year survival with temporal lobe necrosis, with or without treatment, has been reported to be around 59% there .
Owing to its close proximity to the skull base, the medial parts of bilateral temporal lobes are inevitably included in the target volume. Since the inferior portions of the temporal lobes lie within the portals of radiation therapy, TLN is normally seen to occur in bilateral inferomedial parts of the temporal lobes.
Differentiating this condition from metastatic or primary brain tumor remains a clinical and radiological challenge due to their close resemblance. We hereby report the case of a 45 year old Chinese woman with NPC who received radiation therapy at a local hospital using 2D technique and developed severe radiation induced TLN. The diagnosis of TLN, in her case, was missed twice but was finally established by maximal surgical resection and histological examination, hence further laying emphasis on the reduced awareness and diagnostic dilemma of this entity.
TLN, as a late potential sequalae of radiation treatment in patients with NPC, has experienced a down slope over the past decade. This has occurred with the growing worldwide use of IMRT for treatment of this carcinoma which has provided a potentially therapeutic benefit of dose escalation with reduced toxicity to normal tissues . Symptoms of TLN usually appear one to three years after the last dose of radiation treatment with a silent latent interval noted between the end of treatment and development of radiation-induced necrosis . Four main types of clinical presentations were described in a study by Lee et al. They ranged from complete absence of symptoms to vague features of temporal lobe damage, symptoms of temporal lobe epilepsy or nonspecific characteristics of intracranial lesions. The asymptomatic patients were incidentally diagnosed during follow up with CT or MRI . The clinical progression of our patient was that of non-specific symptoms to overt symptoms of raised intracranial pressure.
Using 2D radiotherapy technique, inferior parts of bilateral temporal lobes almost always receive the same dose as the tumor, especially for patients with locally advanced disease infiltrating the skull base or cavernous sinus. It has been reported that there is a 25% chance of developing TLN within 5 years following use of a total dose of equal to or more than 62.5 Gy . The patient received 70 Gy to her skull base using 2D technique which put her at a high risk of developing radiation necrosis. IMRT, on the other hand, has the advantage of generating complicated 3D dose distributions to conform closely to the target volume and the beam intensity can be optimized using computer algorithms. It has been reported that IMRT provided excellent tumor target coverage and allowed the delivery of a high dose to the target with significant sparing of nearby critical normal tissues . Hence, it plays an important role in decreasing radiation-induced injuries in patients with NPC .
The differential diagnoses of TLN include intracranial extension of NPC, second primary intracranial neoplasm, cerebral metastasis, meningeal spread and brain abscess . Differentiation of tumor progression and radiation injury after radiation therapy is indispensable for appropriate treatment . CT, MRI and PET-CT are all useful tools for TLN diagnosis, but none is specific. The characteristic features on MRI include mass effect, vasogenic edema and contrast enhancement. However, MRI alone cannot reliably discriminate tumor from radiation induced necrosis , even though the latter can be associated with specific patterns of enhancement such as "soap bubble" or "Swiss cheese" enhancement patterns . The use of functional imaging like the FDG-PET and the proton MR spectroscopy has shown some advantages in differentiating the entities. But presently, they have not been widely used due to their high cost or complicated techniques. A definitive diagnosis is obtained from surgical exploration and biopsy or removal of the necrotic mass , but this is not routinely justified. It may not strike the doctor to include TLN as one of the differential diagnoses if he does not review the history and treatment plan of the patient. By carefully correlating the history, the findings on physical examination, the laboratory investigations with the features on imaging scans like brain MRI and CT, a correct working diagnosis can be confidently reached without resorting to biopsy [20–22].
In our case report, a brain abscess can be excluded as our patient had few symptoms and signs to support an infectious disease. Ruling out hematogenous spread of NPC is easy, as it is very rare and would unlikely be present bilaterally , while tumor extension is usually associated with erosion of the skull base. Hence, radiation induced necrosis as diagnosis for our patient is supported by the fact that the symptoms developed 6 months after treatment, there was no history of associated fever and the physical findings were consistent with mass effect of the lesion, and last but not the least, the lesions on MRI were bilateral, involving the inferior portions of the temporal lobes, which are usually included in the portals of radiation. However, in our case, this diagnosis may have evaded the attending doctor due to its dwindling existence and close similarity to brain tumor and failure to correlate the bilateralism of the lesions with the treatment plan.
Traditional treatment for TLN includes the use of steroids, hyperbaric oxygen, antiplatelets, anticoagulants, high dose vitamins and surgery, but all have shown a limited efficacy [12, 24]. Steroids have been used to provide prompt symptomatic relief and help in retarding the pathologic process . Surgery is used as the last resort palliative measure in patients with significant increase in intracranial pressure or in those who have progressive neurologic deficits despite steroids or other medical therapy. However, in NPC patients who usually have bilateral temporal lobe involvement, surgery can be hazardous. The possible risk of Kluver Bucy syndrome is of concern when considering bilateral temporal lobectomy . The advent of bevacizumab, a humanized monoclonal antibody that inhibits vascular endothelial growth factor (VEGF) has paved the way to possibilities of reversing the pathogenesis of TLN and providing permanent results. Evidence is now available that justifies the consideration of its use in the treatment of radiation necrosis secondary to treatment of head and neck cancers [26–28].
Although TLN has been dwindling since the introduction of IMRT, it should always be kept in mind when encountering temporal lobe lesions in NPC after radiation therapy. The diagnostic quagmire of TLN lies in its close resemblance to neoplasm on clinical presentation and imaging appearance. This can be achieved by combining the history, physical examination findings, with abnormalities seen on imaging tools like MRI.
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Hildesheim A, Levine PH: Etiology of nasopharyngeal carcinoma: a review. Epidem Rev. 1993, 15: 466-485.Google Scholar
- Marcial VA, Hanley JA, Chang C, Davis LW, Moscol JA: Split-course radiation therapy of carcinoma of the nasopharynx: results of a national collaborative clinical trial of the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1980, 6: 409-414. 10.1016/0360-3016(80)90053-X.View ArticlePubMedGoogle Scholar
- Al-Sarraf M, Pajak TF, Cooper JS, Mohiuddin M, Herskovic A, Ager PJ: Chemo-radiotherapy in patients with locally advanced nasopharyngeal carcinoma: a Radiation Therapy Oncology Group study. J Clin Oncol. 1990, 8: 1342-1351.PubMedGoogle Scholar
- Al-Sarraf M, LeBlanc M, Giri PG, et al: Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroupstudy 0099. J Clin Oncol. 1998, 16: 1310-1317.PubMedGoogle Scholar
- Fischer AW, Holfelder H: lokales amyloid in Gehirn. Dtsch Z Chir. 1930, 227: 475-483.View ArticleGoogle Scholar
- Lee AWM, Law SCK, Ng SH, et al: Retrospective analysis of nasopharyngeal carcinoma treated during 1976-1985:late complications following megavoltage irradiation. Br J Radiol. 1992, 65: 918-928. 10.1259/0007-1285-65-778-918.View ArticlePubMedGoogle Scholar
- Lee AWM, Ng SH, Ho JHC, et al: Clinical diagnosis of late temporal lobe necrosis following radiation therapy for nasopharyngeal carcinoma. Cancer. 1988, 61: 1535-1542. 10.1002/1097-0142(19880415)61:8<1535::AID-CNCR2820610809>3.0.CO;2-E.View ArticlePubMedGoogle Scholar
- Lee AWM, Cheng LOC, Ng SH, et al: Magnetic resonance imaging in the clinical diagnosis of late temporal lobe necrosis following radiotherapy for nasopharyngeal carcinoma. Clin Radiol. 1990, 42: 24-31. 10.1016/S0009-9260(05)81617-4.View ArticlePubMedGoogle Scholar
- Chan JK, Bray F, McCarron P, et al: Nasopharyngeal carcinoma. Pathology and genetics of head and neck tumors. World Health Organization classification of tumors. Edited by: Barnes EL, Eveson JW, Reichart P, Sidransky D. 2005, Lyon, France: IARC Press, 85-97. Feb.4th, 2010Google Scholar
- Greene FL, Page DL, Fleming ID, Editors, et al: AJCC Cancer Staging Manual. 2002, New York: Springer, 47-6Google Scholar
- Teo PML, Ma BBY, Chan ATC: Radiotherapy for nasopharyngeal carcinoma--transition from two-dimensional to three-dimensional methods. Radiother Oncol. 2004, 73: 163-172. 10.1016/j.radonc.2004.06.005.View ArticlePubMedGoogle Scholar
- Giglio P, Gilbert MR: Cerebral radiation necrosis. Neurology. 2003, 9: 180-188. 10.1097/01.nrl.0000080951.78533.c4.View ArticleGoogle Scholar
- Marks JE, Wong J: The risk of cerebral radiation necrosis in relation to dose, time and fractionation. Prog Exp Tumor Res. 1985, 29: 210-218.View ArticlePubMedGoogle Scholar
- Lee N, Xia P, Quivey JM, et al: Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys. 2002, 53: 12-22. 10.1016/S0360-3016(02)02859-6.View ArticlePubMedGoogle Scholar
- Cheng JCH, Chao KSC, Low D: Comparison of Intensity Modulated RadiationTherapy (IMRT) Treatment Techniques for Nasopharyngeal Carcinoma. Int J Cancer (Radiat Oncol Invest). 2001, 96: 126-131. 10.1002/ijc.1004.View ArticleGoogle Scholar
- Glass JP, Hwang TL, Leavens ME, Libshitz HI: Cerebral radiation necrosis following treatment of extracranial malignancies. Cancer. 1984, 54: 1966-1972. 10.1002/1097-0142(19841101)54:9<1966::AID-CNCR2820540930>3.0.CO;2-4.View ArticlePubMedGoogle Scholar
- Schlemmera HP, Bacherta P, Herfartha KK, Zunaa I, Debusa J, van Kaicka G, Proton MR: Spectroscopic Evaluation of Suspicious Brain Lesions After Stereotactic Radiotherapy. Amer J of Neuroradiol. 2001, 22: 1316-1324.Google Scholar
- Bonavita S, Di Salle F, Tedeschi G: Proton MRS in neurological disorders. Eur J Radiol. 1999, 30: 125-131. 10.1016/S0720-048X(99)00051-0.View ArticlePubMedGoogle Scholar
- Kumar AJ, Leeds NE, Fuller GN, et al: Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology. 2000, 217: 377-384.View ArticlePubMedGoogle Scholar
- Martins AN, Johnson JS, Henry JM, Stoffel TJ, Di Chiro G: Delayed radiation necrosis of the brain. J Neurosurg. 1977, 47: 336-345. 10.3171/jns.1977.47.3.0336.View ArticlePubMedGoogle Scholar
- Shaw PJ, Bates D: Conservative treatment of delayed cerebral radiation necrosis. J Neurol Neurosurg Psychiatry. 1984, 47: 1338-1341. 10.1136/jnnp.47.12.1338.PubMed CentralView ArticlePubMedGoogle Scholar
- Safdari H, Castan P, Dubois JB, et al: Lesions cerebrales postradiotherapiques. Rev Neurol (Paris). 1985, 141: 553-561.Google Scholar
- Ho J: Treatment of cancer. 1982, London: Chapman & Hall, 249-Google Scholar
- Glantz MJ, Burger PC, Friedman AH, et al: Treatment of radiation induced nervous system injury with heparin and warfarin. Neurology. 1994, 44: 2020-2027.View ArticlePubMedGoogle Scholar
- Eyster EF, Nielsen SL, Scheline GE, Wilson CB: Cerebral radiation necrosis simulating a brain tumor. J Neurosurg. 1974, 39: 267-271.View ArticleGoogle Scholar
- Gonzales J, Kumar AJ, Conrad CA, Levine VA: Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys. 2007, 67: 323-326. 10.1016/j.ijrobp.2006.10.010.View ArticleGoogle Scholar
- Tocurator R, Zuniga R, Mohan YS, et al: Initial experince with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. J Neurooncol. 2009, 94: 63-68. 10.1007/s11060-009-9801-z.View ArticleGoogle Scholar
- Levin VA, Bidaut L, Hou P, et al: Randomized Double-Blind Placebo-Controlled Trial of Bevacizumab Therapy for Radiation Necrosis of the Central Nervous System. Int J Radiat Oncol Biol Phys.Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.